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OBJECTIVES: To identify subsets of ambulatory care
(outpatient only) quality indicators (QIs) associated with
better survival and physical function outcomes.
DESIGN: Observational cohort study.
SETTING: Pooled data from the Assessing Care of Vul-
nerable Elders (ACOVE)-1 study, which measured quality
of care using 140 care-process QIs, and the subsequent
ACOVE-2 study, which reduced the QIs to 69 ambulatory
care QIs.
PARTICIPANTS: Older adults receiving ambulatory care
(N = 1,015).
MEASUREMENTS: To prioritize and reduce the QIs into
subsets, an expert panel rated each of 69 ambulatory care
QIs for the strength of the link between process and bene-
fit, defined as direct trial evidence on older adults or high
expectation of benefit if a trial were conducted in older
adults. This resulted in three reduced QI sets, reflecting
their intended benefit: 17 QIs for survival (ACOVE Qual-
ity for Survival (AQS)-17), five QIs to preserve function
(AQF-5), and 16 QIs to improve quality-of-life related to
physical health and symptoms (AQQ-16). Whether AQS-
17 would predict 3-year survival was first tested in 1,015
pooled ACOVE-1 and ACOVE-2 participants. Second,
whether AQF-5 (n = 74) and AQQ-16 (n = 359) would
predict change in the Physical Component Summary (PCS)
score of the Medical Outcomes Study 12-item Short-Form
Survey at 1 year was tested in the ACOVE-2 cohort. Con-
trol variables were age, function-based vulnerability, and
comorbidity.
RESULTS: Each 20-percentage-point increment in AQS-
17 was associated with survival (hazard ratio (HR)
= 0.83, P = .01) up to 500 days but not thereafter. AQF-
5, but not AQQ-16, predicted 1-year improvement in PCS
score (1.13-points per 20%-point increment in AQF-5,
P = .02).
CONCLUSION: Subsets of care processes can be linked
with outcomes important to older adults. The AQS-17 and
AQF-5 are potential tools for improving ambulatory care
of older adults. J Am Geriatr Soc 62:1442–1450, 2014.
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Better comprehensive quality of medical care for olderadults with multiple chronic conditions has been
linked to better outcomes.1–3 In the Assessing the Care of
Vulnerable Elders Study (ACOVE-1), composite scores
based on 140 care-process quality indicators (QIs) span-
ning 22 conditions and ambulatory and hospital care4
were associated with better 3-year survival.1 Similarly, bet-
ter quality of care (composite of 120 QIs) of middle-aged
chronically ill adults has been linked to better health-
related quality of life (HRQOL).2 In older adults eligible
for nursing home placement, high-quality care has been
linked to better physical function and survival.3
Nevertheless, there is increasing concern that applica-
tion of multiple clinical guidelines and QIs overburdens
older adults with multiple chronic conditions.5,6 In
ACOVE-1, individuals with three or more conditions
qualified for more than 30 QIs7—with nearly all QIs rep-
resenting more (not less) recommended care. Furthermore,
the need to reduce the ACOVE QIs to a core set of high-
priority ambulatory care QIs (e.g., <30) that could be
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implemented feasibly as a starting point for quality
improvement for populations of individuals was identified.
One proposed approach is to prioritize care processes
with the greatest clinical benefit,8 but ambulatory care QIs
vary greatly with respect to intended clinical benefits.
Although some QIs are aimed at prolonging survival, oth-
ers (e.g., counseling about advanced directives), are unli-
kely to be associated with longer survival. Therefore,
survival, HRQOL, and functional status were used to
identify smaller subsets of QIs that would be associated
with these outcomes, guiding future efforts to improve
care. Addressing older adults’ varying preferences for
healthcare benefits would enhance the quality improve-
ment toolbox.
METHODS
Overview
This was a secondary analysis of data pooled from two
longitudinal ACOVE studies, approved by appropriate
institutional review boards.
Samples
ACOVE-14 and ACOVE-29 have been previously
described. ACOVE-1 tested the feasibility of measuring
13 months of ambulatory and acute quality of care (QOC)
using medical records from 372 participants aged 65 and
older. Using the Vulnerable Elders Survey-13 (VES-13), a
13-item questionnaire based on functional status,10
ACOVE-1 screened two large managed care organizations
for the top one-third of individuals most vulnerable to
death and functional decline. ACOVE-1 found that older
adults received poorer care for geriatric conditions (falls,
dementia, urinary incontinence) than general medical con-
ditions,4 so ACOVE-2 was conducted to improve geriatric
care in primary care practices.
ACOVE-2 measured ambulatory QOC using medical
records from 644 individuals aged 75 and older in two
large multispecialty practices. In contrast to ACOVE-1,
participants were prospectively screened for three geriatric
conditions (urinary incontinence, dementia, falls) rather
than using the VES-13. Other differences are summarized
in Table 1. ACOVE-2 included a controlled practice-
improvement intervention that targeted the care process of
primary care clinicians and administrative staff rather than
participants themselves.11 The intervention improved the
QOC of falls and urinary incontinence but not dementia9
and did not result in unintended decrement in QOC for
nonintervention conditions.12
By combining ACOVE-1 and ACOVE-2 data (1,015
total participants, Figure 1) the effects of QOC and com-
orbidity effects on survival were tested. ACOVE-2 data
only (Figure 1, n = 644) were used to test QOC measures
aimed at preserving physical function and HRQOL.
Quality Measurement
QI development for vulnerable elderly adults has been pre-
viously described.10 ACOVE QIs measure whether clinical
care processes (e.g., prescribing medications or ordering
tests), rather than outcomes of health care (e.g., glycemic
control, mortality), were performed.4 In ACOVE-2, the
140 QIs were streamlined to 69 ambulatory care QIs4
(Figure 1) concerning 12 areas of outpatient preventive
and chronic disease management (Table 1).
In both ACOVE studies, the QIs were applied to mea-
sure QOC for 13 months of documented medical care. Of
the 69 QIs, 12 were aimed at primary prevention (e.g.,
vaccinations) or continuity of care (e.g., advanced direc-
tives) and therefore were measured in more participants.
The remainder were measured based on eligibility criteria
(triggered) based on a participant’s medical diagnoses.
Therefore, a participant with multimorbidity triggered
more QIs than a participant with no chronic conditions. If
a participant refused or could not tolerate recommended
care, the QI was still considered to have been passed. A
subset of QIs was excluded from scoring (not triggered)
based on appropriateness criteria for participants with
advanced dementia or less than 6 months life expec-
tancy.13 A participant-level quality score was calculated
for each participant as number of QIs passed divided by
number of QIs triggered.
Expert Panel Voting for Intended Clinical Benefit
Literature review and expert panel voting was previously
used to establish the validity and appropriateness14–17 of
ACOVE QIs in older adults and to categorize QIs accord-
ing to condition (e.g., diabetes mellitus, dementia) and care
process (e.g., ordering tests, counseling).4,18,19 For this
project, a panel of five physicians (geriatrics, internal medi-
cine) with expertise in QI development and health out-
comes of older adults was convened. The panel
reconsidered the evidence for each QI and three benefits:
survival, preservation of functional status, and HRQOL or
physical symptoms. Using literature that previously sup-
ported each ACOVE ambulatory care QI, the panel voted
on whether each QI was known to have direct link to the
benefit in prior clinical trials of older adults or would be
strongly expected to be linked to the benefit if a trial of
vulnerable older adults was conducted. A QI with neither
rating indicated that the care process was not linked to
that benefit. A link was said to exist between a QI and a
benefit if at least four of the five raters rated the QI as
being known or strongly expected to be linked with the
benefit. A QI could be linked to none, one, or more than
one benefit. The expert panel linked 18 QIs to survival,
five to preserving functional status, and 16 to improving
HRQOL or symptoms (Table 2 and Figure 1), considering
a less than 5-year time frame. Full text of the QIs linked
to benefit are included in Appendix S1. The QIs linked
with any benefit were considered for inclusion as part of a
new benefit-oriented composite QOC score.
Predictor Measures
The primary predictors of interest were participant-level
QOC scores, calculated as the number of QIs passed
divided by the number of QIs for which that participant
was eligible. Of 18 QIs rated as linked to survival
(Table 2), 17 were measured in ACOVE-1 and ACOVE-2
and used to calculate the ACOVE Quality-for-Survival
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score (AQS-17). Five QIs linked to better function were
used to calculate the ACOVE Quality-for-Function score
(AQF-5), and 16 QIs linked to improving HRQOL and
symptoms to calculate the ACOVE Quality for QOL Score
(AQQ-16). Participants were eligible for QOC scores if
they were eligible for at least one QI in that QOC score.
Outcome Measures
Survival was calculated (in days) from enrollment with
censoring at 1,143 days (~3 years, the duration of the
shorter study, ACOVE-1). Survival data were obtained in
ACOVE-1 using names, birth dates, and Social Security
Table 1. Comparisons of the Assessing Care of Vulnerable Elders (ACOVE)-1 and 2 Data Sets Before and After
Pooling
Element
Before Pooling
Pooled Sample for Survival
Outcomes, N = 1,015ACOVE-1, N = 372 ACOVE-2, N = 644
Setting Community-dwelling vulnerable
elderly adults screened from 2
managed care organizations
Large group practices (2 groups
at 7 sites) screened for
symptoms of 3 geriatric
syndromes (falls, dementia, UI)
Age ≥65 (mean 81  6.8) ≥75 (mean 81  4.8) Mean 81  5.6, range 65–100
Female, % 64 65 65
White, % 97 96 96
Vulnerable Elders
Survey-13 score,
mean  SD (range)10
5.3  2.2 (3–10) 4.6  2.6 (1–10)
460 (71%) with scores ≥3
4.9  2.7 (1–10)
Conditions examined, n 15 (atrial fibrillation, coronary
artery disease, congestive heart
failure, chronic renal failure,
dementia, diabetes mellitus,
depression, emphysema, fall,
hypertension, osteoarthritis,
osteoporosis, pressure ulcers,
stroke, urinary incontinence)
12 (atrial fibrillation, coronary
artery disease, congestive heart
failure, dementia, diabetes
mellitus, depression, fall,
hypertension, osteoarthritis,
osteoporosis, stroke, urinary
incontinence)
12 common (atrial fibrillation,
coronary artery disease,
congestive heart failure,
dementia, diabetes mellitus,
depression, fall, hypertension,
osteoarthritis, osteoporosis,
stroke, urinary incontinence)
Total comorbidity count,
mean  SD (range)
2.3  1.5 (range 0–7) 3.5  1.8 (0–10) 3.1  1.8 (0–10)
QIs, n 140 (covering 22 areas of care:
depression, diabetes mellitus,
dementia, falls, hearing loss,
congestive heart failure,
hypertension, coronary artery
disease, osteoarthritis,
osteoporosis, pneumonia,
hospitalization, pressure ulcers,
stroke and atrial fibrillation,
urinary incontinence, continuity
of care, end-of-life, malnutrition,
medication management, pain,
screening and prevention, and
vision care). Participants were
eligible for 8 to 54 QIs
(mean 21).
69 (covering 13 areas of care:
dementia, depression, diabetes
mellitus, falls, hearing
impairment, hypertension,
malnutrition, osteoarthritis,
osteoporosis, pain, urinary
incontinence, medication use,
screening and prevention).
Participants were eligible for
4 to 27 QIs (mean 12).
61 (covering 13 areas of care:
dementia, depression, diabetes
mellitus, falls, hearing
impairment, hypertension,
malnutrition, osteoarthritis,
osteoporosis, pain, urinary
incontinence, medication use,
screening and prevention).
Participants were eligible for
4 to 30 QIs (mean 12).
Primary aim Observational study of feasibility
of measuring ACOVE QIs
Intervention at 2 of 7 sites to
improve care of dementia, falls,
and urinary incontinence;
screening only at 5 control sites
Survival analysis of pooled data
Available outcomes Survival (days) from 0 to 3 years Survival (days) from 0 to 5 years
Quality of life and function
(Medical Health Outcomes 12-
item Short Form-Survey Physical
Component Summary score20)
at 1 year
Survival (days) from 0 to 3 years
Hierarchical data Participants not nested within
physician
Participants nested within 39
different primary care physicians.
Physicians cared for 1–44
participants.
Preliminary testing for cluster
effects of participants within
physician and site but not
included in final models
Other covariables Income, education Income, education Income, education
SD = standard deviation; QI = quality indicator.
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numbers matched to the National Death Index and Social
Security Master Death Files (SS-MDF), whereas ACOVE-2
used names, birth dates, and place of residence matched to
death dates in the SS-MDF supplemented using obituary
searches.
In ACOVE-2 only, HRQOL was collected using the
Medical Outcomes Study 12-item Short Form Survey
(SF-12)20 in 564 interviews during the year after enroll-
ment (mean 10 months). Using the SF-12 responses, each
participant’s Physical Component Summary (PCS) score
(range 0–100; 50 indicating median HRQOL related to
physical function) was calculated.20 PCS score is correlated
with severity of chronic disease symptoms20 and with
function21–23 and has been used as an outcome of quality
of chronic disease care,2 so PCS score was used as a poten-
tial outcome of better AQQ-16 and AQF-5 scores.
Covariables
Medical records for 12 chronic conditions were reviewed
in ACOVE-1 and ACOVE-2 (Table 1). Because ACOVE-2
enrolled participants based on three geriatric conditions
(dementia, falls, incontinence), it had a greater mean num-
ber of conditions than ACOVE-1, which enrolled based on
disabilities rather than comorbidity. Therefore, each study
was divided into tertiles according to comorbidity
counts: low (0–1 conditions for ACOVE-1, 0–2 for
ACOVE-2), moderate (2–3 conditions for ACOVE-1, 3–4
for ACOVE-2), and severe (≥ 4 conditions for ACOVE-1,
≥ 5 for ACOVE-2). Comorbidity was tested as a main and
interaction effect with quality scores.
Other covariables tested were age, sex, an indicator
for ACOVE-1 versus ACOVE-2, and a modified VES-1310
score (age points omitted because age was tested as a
covariable).
Analysis
Data were analyzed at the level of the participant. The
associations between AQS-17 and survival and between
the AQF-5 and AQQ-16 and change in PCS were exam-
ined (Figure 1). P < .05 was considered to be statistically
significant. To present the results in clinically meaningful
units, QOC scores are presented according to increments
of 20 absolute percentage points. If a participant was eligi-
ble for five AQS-17 QIs, then 20 percentage points is
achievable by passing one additional QI.
Cox proportional hazards analysis was used to exam-
ine the association between AQS-17 and survival. Because
AQS-17 violated proportional hazards assumptions, the
time domain was split into two periods, fitting two sepa-
rate Cox regression models. The first model tested survival
from 0 to 500 days; the second from 501 to 1,143 days.
The 500-day cutoff was selected by visually examining the
unadjusted relationship between quality and time until
death. The slope changed at approximately 500 days.
Figure 1. Measure reduction and flow of participant data. Quality indicator (QI) measure development in the Assessing Care of
Vulnerable Elders Study (ACOVE-1) originally included acute and ambulatory care measures and was later reduced to ambula-
tory care–only measures in ACOVE-2. Only QIs measured in both studies were considered for the survival analysis on the pooled
ACOVE-1 and 2 data sets, of which 17 were rated as linked (known or highly likely to be associated) with 3-year survival bene-
fit in older adults. For five QIs rated as linked to better function and 16 QIs with health-related quality of life (HRQOL) or
physical symptom benefits, composite measures of quality were tested on ACOVE-2 participants with available baseline and fol-
low-up interviews using the Medical Outcomes Study 12-item Short-Form Survey Physical Component Summary (PCS) score.
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Within each of the two time periods, it was ensured that
QOC no longer violated the proportional hazard assump-
tion.
Core covariables (age, sex, modified VES-13 score,
comorbidity) were first controlled for. A comorbidity-by-
QOC interaction term was included to test for differences
in benefit between the most- and least-morbid participants.
ACOVE-1 versus ACOVE-2 was also included as a main
and interaction effect with QOC in all survival analyses,
which represented differences in study design and secular
changes in medical care in the 3 years between the two
studies (2000 and 2003, respectively). Models were also
tested for consistency between men and women.
Two exploratory QI-level sensitivity analyses were
performed regarding mortality to examine the individual
QIs in the AQS-17 score. The first QI-level analysis was to
compare mortality in those who passed with that of those
who failed and review for direction of effect (Appendix
S2). The binomial probability test (appropriate for small
samples) was used to review for large differences in mor-
tality between those who passed and those who failed each
QI conservatively using P < .01 as the criterion rather than
P < .05 because most QI-level comparisons were based on
small samples with risk of Type I error. The second
QI-level analysis examined whether the vaccination
QIs (pneumonia and influenza) were driving the survival
Table 2. Quality Indicators (QIs) Rated by Expert Panel as Linked to Intended Clinical Benefits in Older Individu-
als in Ambulatory Care
Condition Short Description of QIa
Clinical Benefit Determined by Panel
Survival
(17 QIs)
Function
(5 QIs)
Quality of Life
Related to
Physical Health
or Symptoms (16 QIs)
All individuals Annual influenza vaccine 9
Pneumococcal vaccine 9
All individuals new
to a clinic
Functional status evaluation on initial exam (ACOVE-2 only) 9
Hearing screen initial evaluation 9 9
Cardiovascular disease Anticoagulant or antiplatelet for high-risk atrial fibrillation 9
Cholesterol intervention for low-density lipoprotein
cholesterol >130 mg/dL if CAD and failed diet intervention
9
Aspirin for individual with CAD 9
Smoking cessation counseling 9
No first- or second-generation calcium channel blockers as first-
line hypertension treatment
9
Beta-blocker for heart failure 9 9
ACE-I or ARB for heart failure 9 9
ACE-I or ARB for hypertension and chronic renal disease 9
Beta blocker after recent (2 years) myocardial infarction 9
Intervention for blood pressure>160 mmHg (ACOVE-2 only)b 9
Dementia New dementia and driving: counseling and notification 9
Cholinesterase inhibitor for mild or moderate dementia 9
Check vitamin B12 and thyroid-stimulating hormone for new
dementia
9 9
Depression screen at initial evaluation 9
Depression New depression: document suicidality and psychosis 9
Depression symptoms, screen within 2 weeks 9
Treat new depression within 2 weeks 9
Change depression treatment by 8 weeks if no response 9
Diabetes mellitus Intervention to decrease blood pressure 9
Daily aspirin therapy 9
ACE-I or ARB for high cardiac risk 9
Cholesterol intervention if total cholesterol >240 mg/dL 9
Falls Exercise or assistive device for balance problem 9 9
Exercise for strength or gait problem 9
Pain management Examination for pain within 1 month 9
Offer treatment for new pain 9
History for pain within 1 month 9
Urinary Incontinence New or persistent incontinence: check urinalysis 9
New incontinence: discuss treatment options 9
Behavior therapy for stress, urge, or mixed incontinence 9
CAD = coronary artery disease; ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker.
aThe full text of each QI is reproduced in the full table in online Appendix S2.
b This QI was the 18th QI rated as having known or highly suspected survival benefit, but it was not developed until Assessing Care of Vulnerable Elders
(ACOVE)-2 and therefore not tested as part of the ACOVE Quality for Survival analysis on pooled ACOVE-1 and ACOVE-2 data.
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benefit because nearly all participants were eligible for
them. By contrast, only half of the participants in the
sample with comorbidities triggered the 15 nonvaccination
QIs in the AQS-17.
To examine associations between AQF-5 and PCS and
between AQQ-16 and PCS (available for ACOVE-2 only
at baseline and 1 year), general linear models were used to
predict change in PCS, controlling for age, sex, ACOVE-2
intervention versus control site, and comorbidity count.
Comorbidity was tested for interaction effects with QOC.
VES-13 was not used because of suspected colinearity with
the outcome variable. Preliminary hierarchical modeling
(with participants clustered within physicians and physi-
cians within sites) were tested but did not change results
from linear models. SAS (SAS Institute, Inc., Cary, NC)
and SPSS (SPSS, Inc., Chicago, IL) were used for all
analyses.
RESULTS
The mean age of the pooled ACOVE-1 and ACOVE-2
populations was 81, and two-thirds were female (Table 1).
Figure 1 shows how the new composite measures were
applied to medical records, determining various samples
from ACOVE-1 and ACOVE-2. Full data were available
for 1,015 of 1,016 participants with an AQS-17 score in
the pooled data sets. These participants were eligible for a
total of 3,268 AQS-17 QIs (mean 3.2  1.7, range 1–11
QIs per participant), and the mean AQS-17 score was
62  34% (interquartile range (IQR) 50–100%). The
AQQ-16 was measured in 513 of the 644 ACOVE-2 par-
ticipants; baseline and follow-up PCS interviews were
available for 359 of these. The AQQ-16 included one QI
(pain treatment) that could be triggered multiple times per
participant. These 359 participants triggered a total of
2,613AQQ-16 QIs (mean 7.3  4.9, range 1–24 QIs per
participant), and the mean AQQ-16 score was 59  31%
(IQR 40–83%). The AQF-5 was measured in 114
participants, 74 of whom had baseline and follow-up PCS
interviews. These 74 participants triggered a total of 122
AQF-5 QIs (mean 1.6  0.6, range 1–3), and the mean
AQF-5 score was 43  43% (IQR 0–100%).
Survival Analysis Results
There were 68 deaths in the first 500 days: 32 (8.6%) in
ACOVE-1 and 36 (5.6%) in ACOVE-2. There were 127
deaths between 501 days and 3 years: 54 in ACOVE-1
(15.9%) and 73 (12%) in ACOVE-2.
In the first 500 days, AQS-17 scores (Table 3, Figure 2)
independently predicted survival (hazard ratio (HR) = 0.83
per 20-percentage-point increment, P = .01). After
500 days, there was no effect (HR = 0.98 per 20-percent-
age-point increment, P = .78). The VES-13 score also pre-
dicted death (HR = 1.29 per point, P < .001). Having the
highest level of comorbidity (but not the middle level) was
associated with worse survival than having the lowest level
(HR = 2.19, P = .03). Age and sex were not related to sur-
vival. There was no difference in AQS-17 effect on sur-
vival according to comorbidity strata (HRQOC 9 moderate
morbidity = 1.08, P = .161; HRQOC 9 high morbidity = 1.07,
P = .31). T
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QI-Level Sensitivity Analyses
Two of the 17 AQS QIs (influenza and pneumonia vacci-
nation) were required in all participants regardless of com-
orbidity and were associated with more crude survival
benefit than the 15 nonvaccination QIs (Appendix S2), so
they were tested as two separate composite QOC scores
(AQS vaccination vs AQS nonvaccination QOC score).
Approximately half (n = 482) were eligible only for the
vaccination AQS-QIs (“simple” participants). The remain-
der of the sample was eligible for vaccinations and at least
one nonvaccination AQS-QI (534 “complex” participants).
The AQS vaccination QOC score was not independently
predictive in the simple, complex, or total sample. The
AQS nonvaccination QOC score was not predictive in the
complex sample (Table 3).
Physical HRQOL Results
The mean follow-up PCS score was 36.7  11.3. PCS score
was stable over time (mean change of +0.4 points, P > .37
for t-test of difference of two means; standard deviation of
change scores = 8.7, range 23-point decline to 28-point
improvement). In the generalized linear models, the AQF-5
(but not the AQQ-16) predicted PCS change (more improve-
ment or less decline). An increment of 20 percentage points
in the AQF-5 score was associated with less decline in PCS
score (b = 1.13-point improvement, standard error (SE)
0.49, P = .02), controlling for age, sex, ACOVE-2 interven-
tion versus control group, and comorbidity. The effect size
for this result was 0.27 (a small effect according to the Co-
hen criteria24). There was no interaction between AQF-5
and intervention group. There was no effect of AQQ-16 on
PCS change score (b = 0.43 points (SE 0.3) per 20-percent-
age-point increment in AQQ-16 score, P > .15). None of
the covariables (age, sex, comorbidity, intervention) pre-
dicted PCS in the AQF-5 or AQQ-16 model.
DISCUSSION
This study aimed to reduce 69 ambulatory care QIs into
smaller subsets of QIs aimed at improving outcomes
important to older adults. Using expert panel review, 17
primary care-processes were classified as linked to survival,
and whether a composite measure of survival-oriented QIs,
the AQS-17 score, would predict better survival was ana-
lyzed. A 20-percentage-point improvement on the AQS-17
was associated with 17% better 500-day survival, indepen-
dent of comorbidity, sex, age, or VES-13 in older adults in
primary care. This modest effect was not detected in the
later observational window (500 days to 3 years), but the
early benefit was consistent in those with higher versus
lower levels of comorbidity burden, sex, age, and vulnera-
bility, as well as between ACOVE-1 and ACOVE-2. Par-
ticular individual QIs did not determine the effect of the
AQS-17; rather, the effect was shared between primary
prevention (e.g., vaccinations) and condition-based care. A
small effect of five QIs aimed at improving functional sta-
tus was also found (1.13 PCS score points per 20 percent-
age points on the AQF-5), but not of 16 QIs aimed at
improving HRQOL in a smaller sample of ACOVE-2 par-
ticipants.
This observational study extends prior observational
research linking better performance on care-process mea-
sures to clinical benefits, including research on vulnerable
older adults1 middle-aged individuals with chronic diseases2
hospitalized older adults,25 and nursing home–eligible indi-
viduals,3 but the link between process and outcome in com-
plex, multimorbid individuals26 with geriatric conditions
(falls, urinary incontinence, dementia) has been limited to
geriatric condition–specific care with condition-specific out-
comes (incontinence-related quality of life27 and falls effi-
cacy28). It is likely that it was possible to link function and
survival with better performance on a composite QOC
measure across conditions because care-processes were
focused on according to their intended benefits.
The implication of this research is that two high-prior-
ity subsets of the ACOVE QIs can be used as a starting
point for future ambulatory care initiatives to improve
care and outcomes of complex older adults. The AQS-17
consisted mostly of cardiovascular care processes but also
considered noncardiovascular care: preventing death in
dementia (due to unsafe driving) and depression (screening
for suicide). These data suggest, but do not prove, that
one approach to prolonging survival might include, as a
starting point, ensuring that these care process QIs are met
in the care of vulnerable older adults. A 20-percentage-
point improvement in QOC, the degree of improvement
that was considered to be clinically meaningful in this
study, is feasible in primary care.9 Although many of the
AQS-17 indicators are similar to current systems-level
measures (e.g., cholesterol control), these results do not
suggest that existing QIs for younger adults should be
extended indefinitely in complex older adults. Rather, the
less-stringent targets for vulnerable elderly adults in the
Lower quality 
(≤ 50% QIs passed, n=456)
Higher quality 
(>50% QIs passed, n=559)
Su
rv
iv
al
First 500 days
Figure 2. Survival of older participants receiving ambulatory
care with higher and lower quality of care using the Assessing
Care of Vulnerable Elders (ACOVE) Survival Quality score.
Adjusted Kaplan-Meier curve up to 500 days, with 1,015 par-
ticipants in pooled ACOVE-1 and 2 samples divided into two
groups: high (score > 50%, upper curve) and low (score
≤ 50%, lower curve) quality. Curves adjusted for comorbidi-
ty, sex, age, ACOVE-1 versus ACOVE-2, and function-based
risk (Vulnerable Elders Survey-13 score). QI = quality indica-
tor.
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ACOVE QIs could potentially be adopted as individuals
become vulnerable (as in ACOVE-1) or develop geriatric
conditions (as in ACOVE-2).
Furthermore, the results suggest that measures used in
quality improvement initiatives can be customized to bene-
fits most important to that population. For vulnerable or
multimorbid older adults, personal preference may help
determine whether to prioritize some care processes such as
those aimed at improving function above survival. Also,
because the AQS-17 can be applied to individuals with
varying burdens of chronic conditions, this suggests a
future approach to improving clinical outcomes in older
adults with multimorbidity, who have traditionally been
excluded from clinical trials. Future quality improvement
aimed at longer survival or better function can target the
prioritized care processes identified in the AQS-17 or AQF-
5 using clinical nurse specialists or care managers within
primary care practices to coordinate better performance.
There are several limitations to interpreting these
results. First, it is important to consider alternative expla-
nations, for example, if poorer care was provided to indi-
viduals who were sicker (e.g., because of preference or
less-aggressive care), but prior work found the opposite;
sicker individuals with greater comorbidity and worse con-
dition severity received better QOC.7,19,29 Therefore, it is
unlikely that these results are due to withholding high-
quality care from those with multimorbidity.
Second, its measurement on a fraction of the eligible
ACOVE-2 sample limited the link between a 20-percent-
age-point absolute improvement in AQF-5 with a 1-point
improvement in PCS. A care process link with quality of
life of similar magnitude has been reported in a study of
middle-aged (rather than older) individuals with chronic
medical conditions.2 The literature on complex interven-
tions to improve functional status also show small or
mixed benefit.30 It is imperative that better functional sta-
tus outcomes measures be developed that are more sensi-
tive to medical interventions31 and quality-of-life measures
that reflect older adults’ values with late-life disability.32
Therefore, if an individual highly values preserving func-
tion above survival, the focus might transition to QI sets
more closely matched to his or her preferences.
Third, future survival-oriented efforts will need to be
updated in response to emerging evidence of survival bene-
fit in older adults. The newer ACOVE-3 QI set includes
hundreds of new QIs not included in an expert panel
review.33 New evidence that hypertension control reduces
mortality34 has emerged since the expert panel was con-
vened, but the QI concerning hypertension control could
not be included in the AQS-17 because it was not mea-
sured until ACOVE-2. All of the AQS-17 QIs, such as
daily aspirin for diabetes mellitus,35 need to be updated.
Fourth, this was an observational study. In contrast to
trials, in which the intervention start date is known, it had
to be presumed that QOC was constant over time. Partici-
pants also could have been receiving better QOC years
before the observation. It is likely that the diminished sur-
vival benefit after 500 days is a limitation of the methods
and should not be interpreted as a reason to stop provid-
ing high AQS-17 care after 500 days.
Fifth, the sample was predominately white, limiting
generalizability of the results to minority groups. Last, it
was not possible to link AQQ-16 scores with PCS scores.
The PCS has limited evidence of responsiveness to changes
in HRQOL in older adults.36 Better measures of HRQOL
and symptoms for older adults with multimorbidities37—
and the healthcare system that can improve these out-
comes38— are needed.
In conclusion, small sets of ambulatory care processes
associated with survival even in vulnerable older adults
with multimorbidity receiving ambulatory care were iden-
tified. Future effort to improve outcomes in these popula-
tions should consider improving and measuring these core
subsets of care processes prioritized according to intended
clinical benefit.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article:
Appendix S1. Quality indicators (QIs) with full text
rated by expert panel as linked with intended clinical bene-
fits in older ambulatory care patients.
Appendix S2. Detailed 3-year mortality results for
each of 17 individual quality indicators used in the AQS-
17, by patients who passed versus failed.
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